×
About 19,415 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  6,513 results

Levofloxacin prophylaxis for pediatric leukemia patients: Longitudinal follow-up for im...
https://doi.org/10.1002/pbc.29525
Pediatric Blood & Cancer; Davis A, Stevens AM et. al.

Jan 15th, 2022 - Bloodstream infections (BSIs) cause morbidity and mortality in pediatric patients with leukemia. Antibiotic prophylaxis during periods of chemotherapy-induced neutropenia may reduce the incidence of BSIs. A levofloxacin prophylaxis guideline was i...

Progress in Transplants for Acute Lymphoblastic Leukemia.
https://doi.org/10.1158/1078-0432.CCR-21-3959
Clinical Cancer Research : an Official Journal of the Ame... Gale RP

Jan 15th, 2022 - Hematopoietic cell transplants are used to treat some adults with acute lymphoblastic leukemia, especially those with high-risk features, such as those with BCR::ABL1. This strategy may be changing given the safety and efficacy of modern tyrosine ...

Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia.
https://doi.org/10.1007/s11899-021-00640-6 10.1056/NEJMra1400972 10.1056/NEJM197312062892312 10.1016/S1470-2045(08)70070-6 10.1200/JCO.2015.64.2850 10.1111/bjh.14411 10.1016/S1470-2045(12)70580-6 10.1001/jamaoncol.2017.0580 10.1002/cncr.32510 10.1002/cncr.31975 10.1200/JCO.2009.22.5060 10.1001/jamaoncol.2018.0089 10.1038/s41375-020-01029-9 10.1016/j.leukres.2019.106232 10.1200/JCO.2016.71.4774 10.1016/j.ejca.2014.02.021 10.1002/pbc.26128 10.1182/blood-2014-08-595108 10.1002/pbc.26182 10.1002/pbc.28294 10.1002/pbc.26191 10.1182/blood-2007-09-112920 10.1200/JCO.2012.43.2070 10.1053/j.seminoncol.2009.05.002 10.1056/NEJM199307293290504 10.1182/blood.V96.10.3381 10.1200/JCO.2003.04.096 10.1200/JCO.2005.03.9727 10.1200/JCO.1996.14.1.18 10.1038/leu.2009.42 10.1007/s00277-017-3002-1 10.1182/blood-2004-11-4544 10.1097/MPH.0b013e3181868570 10.1007/s10555-020-09848-z 10.1111/bjh.13887 10.1038/s43018-020-00115-2 10.1038/leu.2016.272 10.1038/s41586-018-0342-5 10.1080/10428194.2020.1731500 10.1200/JCO.2007.11.8166 10.1182/blood-2013-05-499970 10.1182/blood-2007-04-082040 10.1182/blood-2006-06-027714 10.1200/JCO.2012.47.0500 10.1056/NEJMoa0900386 10.1182/blood-2013-10-532598 10.1038/leu.2009.251 10.1038/leu.2009.257 10.1016/S1470-2045(12)70600-9 10.1200/JCO.20.02529 10.1200/JCO.2003.08.047 10.1002/pbc.24228 10.1182/blood-2015-09-670729 10.1016/S1470-2045(09)70228-1 10.1002/pbc.25620 10.1080/10428190802603169 10.1182/blood-2005-12-011809 10.1200/JCO.19.02892 10.1111/bjh.15983 10.1002/ajh.23784 10.1200/JCO.20.00256 10.1007/s00280-006-0328-0 10.1111/bjh.14877 10.1056/NEJM200004063421402 10.3324/haematol.2018.199422 10.1038/leu.2014.30 10.1046/j.1365-2141.2002.03881.x 10.1200/JCO.2005.03.3373 10.1182/bloodadvances.2020003092 10.1016/j.clml.2020.12.010 10.1007/s00262-020-02829-9 10.1016/j.jns.2020.116706 10.1212/CON.0000000000000936 10.2165/00003088-200948040-00004 10.1007/s40262-013-0106-1 10.1097/MPH.0000000000000642 10.1097/MPH.0000000000000888 10.1054/bjoc.2001.1841 10.1097/00043426-200205000-00011 10.1002/pbc.23317 10.1155/2020/8822172 10.1182/bloodadvances.2019000289 10.1200/JCO.2006.09.7311 10.1182/blood-2012-07-440974 10.1002/ajh.24329
Current Hematologic Malignancy Reports; McNeer JL, Schmiegelow K

Jan 14th, 2022 - The treatment of acute lymphoblastic leukemia (ALL) is one of the success stories of pediatric oncology, but challenges and questions remain, including the optimal approach to the treatment of central nervous system (CNS) leukemia. It is unclear w...

Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low...
https://doi.org/10.1182/bloodadvances.2021006727
Blood Advances; Kotrova M, Koopmann J et. al.

Jan 14th, 2022 - Persistence of minimal residual disease (MRD) after induction/consolidation therapy in acute lymphoblastic leukemia is the leading cause of relapse. The GMALL 07/2003 study used MRD detection by RQ-PCR of clonal immune gene rearrangements with 1x1...

see more →

Guidelines  4 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.

Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...

see more →

Drugs  119 results see all →

Clinicaltrials.gov  282 results

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
https://clinicaltrials.gov/ct2/show/NCT05192889

Jan 14th, 2022 - This is a non-randomized phase I/II clinical trial. In Block I, all patients receiving common therapy evaluating the activity of combination chemotherapy with venetoclax and navitoclax in children with relapsed or refractory acute lymphoblastic le...

Leukemia-Specific Immune Cells (BAFFR- CAR T Cells) for the Treatment of Relapsed or Refractory B-cell ALL
https://clinicaltrials.gov/ct2/show/NCT04690595

Jan 12th, 2022 - This phase I trial evaluates the side effects and best dose of BAFFR-CAR T cells in treating patients with B-cell Acute Lymphoblastic Leukemia that has come back (recurrent) or does not respond to treatment (refractory). T cells are infection figh...

Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Matched Healthy Individuals
https://clinicaltrials.gov/ct2/show/NCT03581045

Jan 11th, 2022 - Cognitive performance (attention and working memory) will be evaluated using the auditory N-Back test. The 0-back condition and the 2-back condition will be used. After cognitive assessment, participants will perform 3 different postural control t...

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
https://clinicaltrials.gov/ct2/show/NCT03016377

Jan 11th, 2022 - LCCC1541-ATL is a Phase I/Phase II dose finding trial to determine if chimeric antigen receptor T (CAR-T) cells targeting the CD19 antigen and containing the inducible caspase 9 safety switch can be safely administered to adult and pediatric subje...

Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BC...
https://clinicaltrials.gov/ct2/show/NCT05182385

Jan 10th, 2022 - Transfer of patients to alloHSCT after one cycle or after a subsequent cycle is considered as per protocol discontinuation and as premature treatment discontinuation. There will be a safety follow-up visit at 30 days after end of the last infusion...

see more →

News  846 results

Improved Survival in ALL Patients Who Relapse After Transplant
https://www.medscape.com/viewarticle/966558

Jan 13th, 2022 - A transplant offers a chance of a cure from leukemia, but when the transplant is not successful, such patients are left with few other options and a poor prognosis. But the management of such patients has been improving, and over the past 20 years...

Examining the Development of T-cell Acute Lymphoblastic Leukemia
https://www.onclive.com/view/examining-the-development-of-t-cell-acute-lymphoblastic-leukemia

Dec 23rd, 2021 - T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive type of leukemia. Despite advances in treatments, patients have an extremely poor prognosis, highlighting the need to explore the genetic components that lead to the formation of T-ALL, ...

Adaptation Is Key to Advancing Care for Adult Patients With Leukemia
https://www.onclive.com/view/adaptation-is-key-to-advancing-care-for-adult-patients-with-leukemia

Dec 21st, 2021 - It would be difficult to look at data involving practice-changing agents for patients with leukemia and miss the name Jorge E. Cortes, MD. An investigative leader for nearly 30 years, Cortes has led the development of numerous leukemia treatments,...

Novel Immunotherapy for Cancer Takes Cue From Transplant Rejection
https://www.medscape.com/viewarticle/964898

Dec 16th, 2021 - NEW YORK (Reuters Health) - A novel immunotherapy treatment works by triggering genetically modified T cells to reject cancer, much as they would a transplanted organ, researchers say. The approach was effective in mouse models and in leukemia cel...

ASH studies look at racial disparities in ALL care, outcomes
https://www.mdedge.com/hematology-oncology/article/249935/all/ash-studies-look-racial-disparities-all-care-outcomes
M. Alexander Otto

Dec 15th, 2021 - Tumor biology and socioeconomics only partly explain why acute lymphoblastic leukemia survival outcomes are worse for young Hispanic and Black patients than White patients, but they don’t explain it entirely, according to a report at the American.

see more →

Patient Education  2 results see all →